Trials / Completed
CompletedNCT07291089
Iris Vascular Area Density-Based Preoperative Pain-Risk Screening and Intervention in Second-Eye Cataract Surgery
Preoperative Pain-Risk Screening and Intervention for Intraoperative Pain in Second-Eye Cataract Surgery Based on Iris Vascular Area Density
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This clinical trial aims to evaluate the effectiveness of pranoprofen or prednisolone acetate eye drops for pain management in patients undergoing second-eye surgery for age-related cataracts. Researchers will compare pranoprofen or prednisolone acetate eye drops with sodium hyaluronate eye drops to determine whether pranoprofen or prednisolone acetate eye drops can relieve intraoperative pain during second-eye cataract surgery. Participants will: 1. Receive one drop in the operative eye at 2 hours, 1.5 hours, 1 hour, and 30 minutes before cataract surgery (pranoprofen, prednisolone acetate, or sodium hyaluronate) 2. Undergo cataract surgery and routine postoperative follow-up 3. Within 1 hour after surgery, provide a pain visual analog scale (VAS) score under the guidance of the investigator
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pranoprofen eye drops | Participants receive one drop of pranoprofen instilled into the operative eye at 2 hours, 1.5 hours, 1 hour, and 30 minutes before cataract surgery. |
| DRUG | Prednisolone acetate eye drops | Participants receive one drop of prednisolone acetate instilled into the operative eye at 2 hours, 1.5 hours, 1 hour, and 30 minutes before cataract surgery. |
| DRUG | Sodium hyaluronate eye drops | Participants receive one drop of sodium hyaluronate instilled into the operative eye at 2 hours, 1.5 hours, 1 hour, and 30 minutes before cataract surgery. |
Timeline
- Start date
- 2024-02-23
- Primary completion
- 2025-11-20
- Completion
- 2025-12-31
- First posted
- 2025-12-18
- Last updated
- 2026-02-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07291089. Inclusion in this directory is not an endorsement.